Autor(es):
Baumann, Michael ; Celis, Julio ; Ringborg, Ulrik ; Heitor, Manuel ; Berns, Anton ; Albreht, Tit ; Arabadjiev, Jeliazko ; Boutros, Michael ; Brandenburg, Mario ; Canhão, Helena ; Carneiro, Fatima ; Chomienne, Christine ; De Lorenzo, Francesco ; Eggermont, Alexander M.M. ; Font, Angel ; Garralda, Elena ; Goulart, Margarida ; Henrique, Rui ; Lawler, Mark ; Maier-Hein, Lena ; Meunier, Francoise ; Oberst, Simon ; Oliveira, Pedro ; Papatriantafyllou, Maria ; Schüz, Joachim ; Solary, Eric ; Valencia, Alfonso ; Vargas, Rosalia ; Weiderpass, Elisabete ; Wilking, Nils
Data: 2023
Identificador Persistente: http://hdl.handle.net/10362/153053
Origem: Repositório Institucional da UNL
Assunto(s): cancer prevention; cancer research; Mission on Cancer; policy; Molecular Medicine; Oncology; Genetics; Cancer Research; SDG 3 - Good Health and Well-being
Descrição
Funding Information: Finally, Dr Garralda highlighted progress made by Cancer Core Europe (CCE), an independent consortium of major cancer centres in Europe that have worked together to create a multi‐site European Cancer Institute, where joint translation and clinical research is performed, with a special focus on next‐generation clinical trials and precision medicine. The creation of large, shared databases through CCE is expected to accelerate cancer diagnosis, clinical decisions, and outcomes research throughout Europe, even when small subsets of cancer patients are targeted. The Basket of Baskets (BoB) multimodal clinical trial design and the CCE Molecular Tumour Board exemplify how the above can be achieved [ 22,23 ] and have further developed with the recent funding from the EU's Horizon 2020 research and innovation programme to build data‐rich clinical trials (DART). The DART project was launched in February 2021, with the aim to develop digital tools for trial management and clinical decision‐making. DART is expected to improve clinical trial methodology through the introduction of new statistical designs. Moreover, it aims at integrating more accurate imaging and molecular biomarkers of treatment responses into a new generation of clinical trials, while also ensuring patient empowerment and involvement or engagement (Table 2 ). Funding Information: Research discussed by Elena Garralda has been funded by CaixaResearch Advanced Oncology Research Program supported by Fundació La Caixa (LCF/PR/CE07/50610001) and by the European Union under grant agreements no. 965397 (CC‐DART) and 101079984 (PCM4EU). Authors are grateful to Christina von Gertten for preparation of the manuscript. Publisher Copyright: © 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
European cancer research stakeholders met in October 2022 in Heidelberg, Germany, at the 5th Gago conference on European Cancer Policy, to discuss the current cancer research and cancer care policy landscape in Europe. Meeting participants highlighted gaps in the existing European programmes focusing on cancer research, including Europe's Beating Cancer Plan (EBCP), the Mission on Cancer (MoC), Understanding Cancer (UNCAN.eu), and the joint action CRANE, and put forward the next priorities, in the form of the Heidelberg Manifesto for cancer research. This meeting report presents all discussions that shed light on how infrastructures can be effectively shaped for translational, prevention, clinical and outcomes cancer research, with a focus on implementation and sustainability and while engaging patients and the public. In addition, we summarize recommendations on how to introduce frameworks for the digitalization of European cancer research. Finally, we discuss what structures, commitment, and resources are needed to establish a collaborative cancer research environment in Europe to achieve the scale required for innovation.
